Oxylanthanum Carbonate (OLC)
Hyperphosphatemia in Chronic Kidney Disease (CKD)
NDA SubmittedActive
Key Facts
Indication
Hyperphosphatemia in Chronic Kidney Disease (CKD)
Phase
NDA Submitted
Status
Active
Company
About Unicycive Therapeutics
Unicycive Therapeutics is an agile, clinical-stage biotech focused exclusively on developing innovative therapies for kidney disease. Its strategy centers on in-licensing or acquiring promising, overlooked assets and advancing them with speed and operational efficiency. The company's lead asset, Oxylanthanum Carbonate (OLC), has an FDA PDUFA date of June 29, 2026, positioning it for a potential near-term commercial launch in the multi-billion dollar hyperphosphatemia market.
View full company profile